After Novo and Lilly resolved GLP-1 shortages, where does the compounding industry stand? Experts weigh in
While concerns over pricing and access to Novo’s Wegovy and Lilly’s Zepbound persist, especially given the sheer number of people who received replicated versions while the meds were in shortage, indulging compounders who continue to sell cheaper copycats en masse is misguided, multiple experts have cautioned.
While concerns over pricing and access to Novo’s Wegovy and Lilly’s Zepbound persist, especially given the sheer number of people who received replicated versions while the meds were in shortage, indulging compounders who continue to sell cheaper copycats en masse is misguided, multiple experts have cautioned.
